

OCT 1 9 2001

KD13153

Section 9
510(K) SUMMARY

SPONSOR: Boston Scientific Corporation (BSC)
Microvasive Endoscopy Division
One Boston Scientific Place
Natick, MA 01760

CONTACT/SUBMITTER: Lisa Quaglia
Regulatory Affairs Manager
Tel: 508-650-8267

DATE OF SUBMISSION: September 19, 2001

DEVICE: Autotome™ RX

Trade Name: Autotome™ RX
Common Name: Sphincterotome
Classification: Endoscope and Accessories
Classified Under 21 CFR Part 876, §4300.
Classified as a Class II Device.

PREDICATE DEVICE: Rapid Exchange™ Cannulating Sphincterotome
(K970053, Ultratome RX)

DEVICE DESCRIPTION: The proposed Autotome™ RX is a triple lumen sphincterotome with controlled orientation and rotation features. It is compatible with the Boston Scientific Microvasive® Endoscopy's Rapid Exchange™ platform, and is capable of accommodating a .035" guidewire while allowing simultaneous injection through an adjacent lumen.

INTENDED USE: The Autotome™ RX is indicated for use in transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi. This device can also be used to cannulate and inject contrast medium.

COMPARISON OF CHARACTERISTICS: The proposed device is substantially equivalent to currently marketed devices used for transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi, and for injection of contrast media into the biliary and pancreatic ductal systems.

PERFORMANCE DATA: The proposed device is substantially equivalent to currently marketed Rapid Exchange™ Cannulating Sphincterotome in terms of performance characteristics tested and biocompatibility.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

OCT 19 2001

Ms. Lisa M. Quaglia
Regulatory Affairs Manager
Microvasive Endoscopy
Boston Scientific Corporation
One Boston Scientific Place
NATICK MA 01760-1537

Re: K013153
Trade/Device Name: Ultratome™ RX
Model # 4515, 4516
Regulation Number: 21 CFR 876.4300
Regulation Name: Endoscopic electrosurgical
unit and accessories
Regulatory Class: II
Product Code: 78 KNS
Dated: September 19, 2001
Received: September 20, 2001

Dear Ms. Quaglia:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known)

K013153

Page 1 of 1

Device Name

Autotome™ RX

Indications for Use

The Autotome™ RX is indicated for use in transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi. The device can also be used to cannulate and inject contrast medium.

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒
 (Per 21 CFR 801.109)

OR

Over the Counter Use ☐


(Division Sign-Off)

Division of Reproductive, Abdominal,
and Radiological Devices

510(k) Number

K013153